Trending Now

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Streetwise Reports (11/23/2022)

Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.

Tags: Biotechnology / Pharmaceuticals

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report

Dr. Andre Uddin (11/22/2022)

During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Blockchain Co. Signs Agreement With Insurance Co.

Streetwise Reports (11/22/2022)

Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.

Tags: CannabisTechnologyCryptocurrency / Blockchain

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report

Dr. Yale Jen (11/22/2022)

The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Tags: Biotechnology / Pharmaceuticals

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Streetwise Reports (11/22/2022)

Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.

Tags: Biotechnology / Pharmaceuticals

FDA Awards Breakthrough Therapy Status for AMD Drug

Streetwise Reports (11/21/2022)

Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report

Dr. Andre Uddin (11/18/2022)

The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hopes To Turn US$30M Into US$2B

Streetwise Reports (11/17/2022)

CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Streetwise Reports (11/16/2022)

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

UK Co. Buys NARCAN® Nasal Spray Maker

Streetwise Reports (11/14/2022)

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

Streetwise Reports (11/14/2022)

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Streetwise Reports (11/11/2022)

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Tags: Biotechnology / Pharmaceuticals

Biologics Co. Doubles Revenue in Q3/22

Streetwise Reports (11/11/2022)

ADMA Biologics Inc. shares traded 27.5% higher after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Trades 200% Higher

Streetwise Reports (11/10/2022)

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.

Tags: Biotechnology / Pharmaceuticals

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion

Penny Queen (11/09/2022)

With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

"RHT added 50 new nursing home clients in Florida to its network."

–Douglas Loe, Leede Jones Gable

"The dip of recent days presents us with a better entry point for RHT."

–Clive Maund, CliveMaund.com

"PMN expects to file an NDA for PMN310 with the FDA by 2022E."

–Steve Silver, Argus Research

"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com

"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com

"This is a good time to buy PMN stock."

–Clive Maund, CliveMaund.com

"PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

–Douglas Loe, Leede Jones Gable

"We are positive about PMN's PMN-310 possibly mitigating AD progression."

–Douglas Loe, Leede Jones Gable

"A minor relief rally in the broad market could see AGN shoot up again."

–Clive Maund, CliveMaund.com

"The case for buying AGN here could scarcely be stronger."

–Clive Maund, CliveMaund.com

"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com

"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com

"Experiments showed that PMN's PMN310 has a unique binding profile."

–Douglas Loe, Leede Jones Gable

"AGN is considered to be at another good buy spot here."

–Clive Maund, CliveMaund.com

"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation

"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation

"RHT's quality of net income earnings is extremely high."

–Jefferson Research

"PMN designated PMN267 as its lead candidate for treatment of ALS."

–Steve Silver, Argus Research

"PMN's PMN310 could benefit from favorable FDA review of lecanemab."

–Douglas Loe, Leede Jones Gable

"PMN's PMN310 potentially represents a best-in-class opportunity."

–Steve Silver, Argus Research

Tune In to Our NEW Podcast: Streetwise Listens

NASDAQ Biotech ARCA Pharmaceutical

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion

Clive Maund (11/09/2022)

Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Tags: GoldBiotechnology / PharmaceuticalsCritical MetalsTechnologyBase MetalsSilver

Medical Device Co.'s Q2/22 Results Better Than Expected

Research Report

Dr. Andre Uddin (11/09/2022)

Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.

Tags: Medical Devices

Pharma Co. Signs Global License Deal for Eye Drops

Streetwise Reports (11/08/2022)

Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.

Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Offers US$295M for Ophthalmology Co.

Streetwise Reports (11/08/2022)

Shares of Oyster Point Pharma Inc. traded 38.5% higher after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.

Tags: Biotechnology / Pharmaceuticals

Organ Transplant Co.'s Q3 Revenues Rise 378%

Streetwise Reports (11/04/2022)

Shares of medical technology firm TransMedics Group Inc. traded 24% higher to a new 52-week high after the company reported Q3/22 financial results highlighting a 378% YoY increase in net revenue and raised its FY/22 revenue estimates to US$80-85 million.

Tags: Healthcare ServicesLife Sciences Tools & DiagnosticsMedical Devices

Telemedicine Co. Surges on Revenue News

Streetwise Reports (11/04/2022)

As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.

Tags: Life Sciences Tools & DiagnosticsTechnologyHealthcare Services

The Life Sciences Report

Trending Now

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Life Sciences Co. Exceeds Expectations in Q3/22

Blockchain Co. Signs Agreement With Insurance Co.

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

FDA Awards Breakthrough Therapy Status for AMD Drug

Pharma Co. Won't See Bump in Sales From New COVID Drug

Biopharma Co. Hopes To Turn US$30M Into US$2B

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

UK Co. Buys NARCAN® Nasal Spray Maker

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Biologics Co. Doubles Revenue in Q3/22

Pharma Co. Trades 200% Higher

Clean Nuclear Med Tech With Quantum Blue Sky

Expert Investing Ideas

Tune In to Our NEW Podcast: Streetwise Listens

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

Nine Stocks Expert Says Should Pique Your Interest

Medical Device Co.'s Q2/22 Results Better Than Expected

Pharma Co. Signs Global License Deal for Eye Drops

Healthcare Firm Offers US$295M for Ophthalmology Co.

Organ Transplant Co.'s Q3 Revenues Rise 378%

Telemedicine Co. Surges on Revenue News

Enter a valid ticker symbol below or start typing for suggestions.